New Long Term Data Add to Ilyang CML Drug Promise
This article was originally published in PharmAsia News
Executive Summary
South Korea's mid-size pharma firm Ilyang Pharm has presented promising new clinical results for its leukemia therapy Supect (radotinib; IY5511), which is the first original drug for the disease to be developed in Asia.